Suppr超能文献

评估临床前肿瘤异种移植模型中的细胞毒性治疗效果。

Assessing cytotoxic treatment effects in preclinical tumor xenograft models.

作者信息

Wu Jianrong, Houghton Peter J

机构信息

Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee 38105-3678, USA.

出版信息

J Biopharm Stat. 2009 Sep;19(5):755-62. doi: 10.1080/10543400903105158.

Abstract

In preclinical solid tumor xenograft experiments, tumor response to cytotoxic agents is often assessed by tumor cell kill. Log10 cell kill (LCK) is commonly used to quantify the tumor cell kill in such experiments. For comparisons of antitumor activity between tumor lines, the LCK values are converted to an arbitrary rating; for example, the treatment effect is considered significant if the LCK > 0.7 (Corbett et al., 2003). The drawback of using such a predefined cutoff point is that it does not account for the true variation of the experiments. In this article, a nonparametric bootstrap percentile interval of the LCK is proposed. The cytotoxic treatment effect can be assessed by the confidence limits of the LCK. Monte Carlo simulations are conducted to study the coverage probabilities of the proposed interval for small samples. Tumor xenograft data from a real experiment are analyzed to illustrate the proposed method.

摘要

在临床前实体瘤异种移植实验中,肿瘤对细胞毒性药物的反应通常通过肿瘤细胞杀伤来评估。对数10细胞杀伤(LCK)常用于在此类实验中量化肿瘤细胞杀伤。为了比较不同肿瘤细胞系之间的抗肿瘤活性,LCK值会被转换为一个任意等级;例如,如果LCK > 0.7,则认为治疗效果显著(Corbett等人,2003年)。使用这样一个预定义的截止点的缺点是它没有考虑到实验的真实变异性。在本文中,提出了LCK的非参数自助百分位数区间。细胞毒性治疗效果可以通过LCK的置信限来评估。进行蒙特卡洛模拟以研究该提议区间对小样本的覆盖概率。分析来自一项实际实验的肿瘤异种移植数据以说明所提出的方法。

相似文献

1
Assessing cytotoxic treatment effects in preclinical tumor xenograft models.
J Biopharm Stat. 2009 Sep;19(5):755-62. doi: 10.1080/10543400903105158.
2
Assessment of antitumor activity for tumor xenograft studies using exponential growth models.
J Biopharm Stat. 2011 May;21(3):472-83. doi: 10.1080/10543406.2010.481802.
3
Interval approach to assessing antitumor activity for tumor xenograft studies.
Pharm Stat. 2010 Jan-Mar;9(1):46-54. doi: 10.1002/pst.369.
4
Statistical inference for tumor growth inhibition T/C ratio.
J Biopharm Stat. 2010 Sep;20(5):954-64. doi: 10.1080/10543401003618983.
6
Joint longitudinal and survival-cure models in tumour xenograft experiments.
Stat Med. 2014 Aug 15;33(18):3229-40. doi: 10.1002/sim.6175. Epub 2014 Apr 20.
7
Improved statistical modeling of tumor growth and treatment effect in preclinical animal studies with highly heterogeneous responses in vivo.
Clin Cancer Res. 2012 Aug 15;18(16):4385-96. doi: 10.1158/1078-0432.CCR-11-3215. Epub 2012 Jun 27.
8
Biomarker- versus drug-driven tumor growth inhibition models: an equivalence analysis.
J Pharmacokinet Pharmacodyn. 2015 Dec;42(6):611-26. doi: 10.1007/s10928-015-9427-z. Epub 2015 Jul 26.
9
A simulation-based sample size calculation method for pre-clinical tumor xenograft experiments.
J Biopharm Stat. 2018;28(3):437-450. doi: 10.1080/10543406.2017.1315820. Epub 2017 Apr 27.

引用本文的文献

2
Confidence intervals for the difference of median failure times applied to censored tumor growth delay data.
Stat Biopharm Res. 2011;3(3):488-496. doi: 10.1198/sbr.2011.10020. Epub 2012 Jan 24.
3
A simulation-based sample size calculation method for pre-clinical tumor xenograft experiments.
J Biopharm Stat. 2018;28(3):437-450. doi: 10.1080/10543406.2017.1315820. Epub 2017 Apr 27.
4
Inhibitor of MYC identified in a Kröhnke pyridine library.
Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12556-61. doi: 10.1073/pnas.1319488111. Epub 2014 Aug 11.
5
Assessing interactions for fixed-dose drug combinations in subcutaneous tumor xenograft studies.
Pharm Stat. 2013 May-Jun;12(3):115-9. doi: 10.1002/pst.1559. Epub 2013 Mar 7.
6
Assessment of antitumor activity for tumor xenograft studies using exponential growth models.
J Biopharm Stat. 2011 May;21(3):472-83. doi: 10.1080/10543406.2010.481802.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验